The hope for neglected diseases: R&D incentives

Brigitte Granville and Eshref Trushin

No 35, Working Papers from Queen Mary, University of London, School of Business and Management, Centre for Globalisation Research

Abstract: Neglected diseases are neglected because they cannot generate enough return on R&D to pharmaceutical firms. This paper analyzes and compares existing proposals for public intervention in R&D for neglected diseases. Incentives for neglected diseases are comprehensively evaluated based on seventeen selected criteria grouped into four categories: efficiency, feasibility, fairness, and sustainability. Our conclusion is that public-private partnerships coordinated through a centralized service platform have the highest potential to satisfy the criteria for the successful development..

Keywords: neglected diseases; incentives; pharmaceutical R&D; policy analysis (search for similar items in EconPapers)
JEL-codes: H41 H87 I12 I18 (search for similar items in EconPapers)
Date: 2010-08
New Economics Papers: this item is included in nep-hea, nep-ino, nep-ipr and nep-pr~
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
http://cgr.sbm.qmul.ac.uk/CGRWP35.pdf

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:cgs:wpaper:35

Access Statistics for this paper

More papers in Working Papers from Queen Mary, University of London, School of Business and Management, Centre for Globalisation Research Contact information at EDIRC.
Bibliographic data for series maintained by Pedro S. Martins ().